CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
血液系统恶性肿瘤 CAR-T 细胞治疗后的长期生存
英文原题：Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies.
查看英文原题
Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
临床试验和真实世界证据已确立嵌合抗原受体（CAR）T细胞疗法可降低血液系统恶性肿瘤进展风险，并在部分情境下延长总生存期。然而，近期研究指出，长期缓解患者仍面临发病和非复发死亡风险，主要原因是感染及后续髓系恶性肿瘤。此外，这些患者也可能曾接受化疗、放疗和/或干细胞移植，因而有广泛的生存期照护需求。本文为CAR-T 治疗后长期缓解患者的照护提出路线图，并讨论未来研究方向。
展开英文摘要原文
Clinical trials and real-world evidence have established the benefit of chimeric antigen receptor (CAR) T-cell therapy to reduce progression of hematologic malignancies and, in some settings, increase overall survival.
However, recent studies have highlighted that patients in long-term remission remain at risk of morbidity and nonrelapse mortality, primarily because of infections and subsequent myeloid malignancies.
In addition, these patients may also be survivors of chemotherapy, radiation, and/or stem-cell transplant, with broad survivorship needs.
Here, we provide a roadmap for the care of patients in long-term remission after CAR-T-cell therapies and discuss avenues for future research.
论文信息
- 作者
- Faramand RG、Xie Z、Jain MD
- 单位
- Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.United States
- 文献类型
- 综述
- 期刊
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology2026 Mar 10
- 原文标识
- PubMed 41671523 · DOI 10.1200/JCO-25-02087